Asceneuron SA’s Post

Erickson, C.M., Chin, N.A., Ketchum, F.B. et al. The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer’s Biomarker Results to Research Participants. J Prev Alzheimers Dis11, 1–6 (2024). https://lnkd.in/dy-UyHMJ Disclosing Alzheimer’s disease (AD) biomarkers to research participants is a growing practice. Here, we aim to synthesize the experiences of clinicians leading preclinical AD biomarker disclosure.

Proud to see C-Path's collaboration with The Michael J. Fox Foundation for Parkinson's Research on advancing Parkinson’s disease therapeutics through the use of the α-synuclein seed amplification assay biomarker featured in NeurologyLive. In the article, Diane Stephenson, Executive Director of the Critical Path for Parkinson's Consortium, emphasizes the significance of this breakthrough: “The new biomarker findings that have emerged in the last two years are truly transforming how we're going to be doing drug development for the future of Parkinson's... We now have a molecular tool that shows us the underlying biology of the disease in living individuals, allowing us to identify the right people to treat with promising new therapies, even years before symptoms appear." This coverage highlights the incredible progress made in PD research, particularly how this biomarker will help accelerate clinical trials and bring us closer to new, effective treatments for those impacted by the disease. Read the full article here: https://lnkd.in/g9rWJBzi #CPath #Parkinsons #DrugDevelopment #NeurologyLive #Collaboration #ParkinsonsDisease #BiomarkerResearch #ClinicalTrials #Innovation

Discover how precision medicine is revolutionizing healthcare beyond oncology in this insightful article from our ZS Precision Medicine COE. Learn about the potential of personalized treatments, genomics, and data-driven approaches to transform patient care across various therapeutic areas. From cardiovascular diseases to rare genetic disorders, precision medicine holds immense promise in tailoring treatments to individual patients. Explore the latest advancements and opportunities in this exciting field that is reshaping the future of healthcare. Read more: https://lnkd.in/e9CqJn87 #PrecisionMedicine #HealthcareTransformation"

In business news from the antibody diagnostics space, Alamar Biosciences, Inc. Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced a strategic supply agreement with ALZpath Inc., a leading developer of diagnostic solutions in Alzheimer’s disease and related dementias. This collaboration marks a significant milestone in the advancement of novel tools for neurodegenerative disease research. The focal point of this partnership is the ALZpath pTau217 (phosphorylated tau at position 217) antibody, a crucial tool in the investigation of Alzheimer’s disease and various other neurodegenerative disorders. The ALZpath pTau217 antibody provides researchers with a highly sensitive and specific tool for the detection and analysis of pathological changes associated with Alzheimer’s disease. #mabs https://lnkd.in/egcJJqab

𝗘𝗻𝗲𝗿𝗴𝘆 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘀𝗺: 𝗰𝗼𝗿𝗻𝗲𝗿𝘀𝘁𝗼𝗻𝗲 𝗳𝗼𝗿 𝟯𝗣𝗠 𝗶𝗻 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 "... a precise metabolic phenotyping ... is crucial to improve individual outcomes ...". That's a quote from the article that I'd like to highlight today. Well, of course changes in energy metabolism are well-established to be a hallmark of cancer - including but not limited to lung cancer. However, energy metabolism is highly dynamic and quite a few energy metabolism-related compounds are difficult from an analytical perspective. The review discusses relevant pathways as well as the potential of (multi-)omics analyses to personalize therapies based on an indiviual patient's energy metabolism, with a focus on factors related to mitochondrial health. https://lnkd.in/dWBi58XK Full publication: Ousman Bajinka, Serge Yannick Ouedraogo, Olga Golubnitschaja, Na Li. Xianquan Zhan. Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine. EPMA Journal (2024). https://lnkd.in/dTFZWszu. Freely available under a Creative Commons license: https://lnkd.in/dyuva2r8 #science #metabolism #pharmacology #oncology #precisionmedicine

https://lnkd.in/dv-Txvxa PRECAME Study: Preventing cardiovascular effects with metformin in obese patients ( Corpori Sano Biotechnology & Walter LAB, Brasil 🇧🇷 2002 ) " A new therapeutic approach in cardiovascular, metabolic and oncological prevention " " Specific therapy, to live healthily " " Drug that modulates mitochondrial, endothelial and DNA-telomere function " " Creating a scientific basis for an infinite possibility of future studies and research " " The era of insulin resistance modulators, ability to alter the cellular regulatory circuit " " Insulin resistance sensitiizers or modulators: Therapeutic link between human metabolism, cardiovascular system and cancer " " Through innovative medicines for public health and commited to bringing better health and a better future for patients, translating science and regenerative medicine into medicines that change human lives, as the main objective " " PRECAME Study and Walter's Metabolic Theory, improving the perspective and quality of life of patients " #health #science #ciencia #healthcare #oncology #cancer #obesity #insulinresistance #breastcancer #cellculture #immunology #atherosclerosis #celltherapy #prevention #innovation #obesidade

Biologics are complex medicines made by living cells that can, because of their larger and more complex molecular structure, provide precise and personalized treatments with potentially fewer side effects and safety concerns. Therapeutic antibodies are now being explored for their potential in treating infectious and neurodegenerative diseases, metabolic disorders, and cardiovascular conditions, showcasing their expanding role in modern medicine. Working across immunology and neuroscience, Teva is focused on identifying highly targeted antibodies to fight disease. With recent launches and an extensive pipeline, Teva has acquired industry-leading experience in screening and selecting disease-fighting antibodies for effective therapies. Discover more about Teva’s innovative work in this space: https://lnkd.in/d3rdC7Mc #InnovativeMedicines #WeAreAllInForBetterHealth

Exciting news in Alzheimer's research! Revolutionary blood biomarkers are changing the game in diagnostics and treatment. Traditional methods like imaging and cerebrospinal fluid testing often pose challenges due to their invasiveness. Enter Mayo Clinical Laboratories' latest breakthrough: a noninvasive plasma biomarker assay, discussed by Dr. Alicia Algeciras-Schimnich in a recent episode of "Answers From the Lab" podcast. Tailored for individuals aged 50 and above, this assay offers accessible and accurate testing without invasive procedures. Dr. Algeciras-Schimnich emphasizes the significance of this advancement in evaluating mild cognitive impairment and determining eligibility for disease-modifying therapies. Clinically validated through rigorous Mayo Clinic research, this immunoassay identifies phosphorylated Tau 217 (p-Tau217) with an impressive sensitivity of 92% and specificity of 96%. With disease-modifying therapies now available, biomarker testing for Alzheimer's is becoming essential in clinical evaluations, offering rapid and scalable solutions for detecting amyloid pathology. Excited to learn more? Tune in to the podcast for a deep dive into Mayo Clinic Laboratories' cutting-edge plasma biomarker testing for Alzheimer's disease (https://lnkd.in/dY_HkCU5)!  #Mayocliniclaboratory #Alzheimers #AD #MedicalInnovation #BloodTest #ResearchBreakthrough

Biologics are complex medicines made by living cells that can, because of their larger and more complex molecular structure, provide precise and personalized treatments with potentially fewer side effects and safety concerns. Therapeutic antibodies are now being explored for their potential in treating infectious and neurodegenerative diseases, metabolic disorders, and cardiovascular conditions, showcasing their expanding role in modern medicine. Working across immunology and neuroscience, Teva is focused on identifying highly targeted antibodies to fight disease. With recent launches and an extensive pipeline, Teva has acquired industry-leading experience in screening and selecting disease-fighting antibodies for effective therapies. Discover more about Teva’s innovative work in this space: https://lnkd.in/ghddDTsx #InnovativeMedicines #WeAreAllInForBetterHealth

Biologics are complex medicines made by living cells that can, because of their larger and more complex molecular structure, provide precise and personalized treatments with potentially fewer side effects and safety concerns. Therapeutic antibodies are now being explored for their potential in treating infectious and neurodegenerative diseases, metabolic disorders, and cardiovascular conditions, showcasing their expanding role in modern medicine. Working across immunology and neuroscience, Teva is focused on identifying highly targeted antibodies to fight disease. With recent launches and an extensive pipeline, Teva has acquired industry-leading experience in screening and selecting disease-fighting antibodies for effective therapies. Discover more about Teva’s innovative work in this space: https://lnkd.in/dkkBtzUK #InnovativeMedicines #WeAreAllInForBetterHealth